BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 22003067)

  • 1. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
    Kreitman RJ; Pastan I
    Clin Cancer Res; 2011 Oct; 17(20):6398-405. PubMed ID: 22003067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moxetumomab Pasudotox: First Global Approval.
    Dhillon S
    Drugs; 2018 Nov; 78(16):1763-1767. PubMed ID: 30357593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoconjugates in the management of hairy cell leukemia.
    Kreitman RJ; Pastan I
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):236-45. PubMed ID: 26614902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxetumomab pasudotox for the treatment of hairy cell leukemia.
    Janus A; Robak T
    Expert Opin Biol Ther; 2019 Jun; 19(6):501-508. PubMed ID: 31045462
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
    Wayne AS; Shah NN; Bhojwani D; Silverman LB; Whitlock JA; Stetler-Stevenson M; Sun W; Liang M; Yang J; Kreitman RJ; Lanasa MC; Pastan I
    Blood; 2017 Oct; 130(14):1620-1627. PubMed ID: 28983018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
    Kreitman RJ; Tallman MS; Robak T; Coutre S; Wilson WH; Stetler-Stevenson M; Fitzgerald DJ; Lechleider R; Pastan I
    J Clin Oncol; 2012 May; 30(15):1822-8. PubMed ID: 22355053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia.
    Abou Dalle I; Ravandi F
    Expert Rev Hematol; 2019 Sep; 12(9):707-714. PubMed ID: 31298972
    [No Abstract]   [Full Text] [Related]  

  • 8. Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations.
    Nobre CF; Newman MJ; DeLisa A; Newman P
    Cancer Chemother Pharmacol; 2019 Aug; 84(2):255-263. PubMed ID: 31134324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
    Kreitman RJ; Dearden C; Zinzani PL; Delgado J; Robak T; le Coutre PD; Gjertsen BT; Troussard X; Roboz GJ; Karlin L; Gladstone DE; Kuptsova-Clarkson N; Liu S; Patel P; Rotolo F; Mitry E; Pastan I; Giles F;
    J Hematol Oncol; 2021 Feb; 14(1):35. PubMed ID: 33627164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
    Kreitman RJ; Pastan I
    Oncologist; 2020 Jan; 25(1):e170-e177. PubMed ID: 31628266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval.
    Lin AY; Dinner SN
    Blood Adv; 2019 Oct; 3(19):2905-2910. PubMed ID: 31594764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxetumomab Pasudotox in Hairy Cell Leukaemia: A Profile of Its Use.
    Kang C
    Clin Drug Investig; 2021 Sep; 41(9):829-834. PubMed ID: 34383256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.
    Onda M; Beers R; Xiang L; Nagata S; Wang QC; Pastan I
    Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11311-6. PubMed ID: 18678888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.
    Short NJ; Kantarjian H; Jabbour E; Cortes JE; Thomas DA; Rytting ME; Daver N; Alvarado Y; Konopleva M; Kebriaei P; Wierda WG; DiNardo CD; Bivins C; McCue D; Richie MA; Ravandi F
    Br J Haematol; 2018 Aug; 182(3):442-444. PubMed ID: 28616864
    [No Abstract]   [Full Text] [Related]  

  • 15. Moxetumomab pasudotox: A first-in-class treatment for hairy cell leukemia.
    Fancher KM; Lally-Montgomery ZC
    J Oncol Pharm Pract; 2019 Sep; 25(6):1467-1472. PubMed ID: 30917739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.
    Onda M; Beers R; Xiang L; Lee B; Weldon JE; Kreitman RJ; Pastan I
    Proc Natl Acad Sci U S A; 2011 Apr; 108(14):5742-7. PubMed ID: 21436054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.
    Bera TK; Onda M; Kreitman RJ; Pastan I
    Leuk Res; 2014 Oct; 38(10):1224-9. PubMed ID: 25127689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotoxins in the treatment of refractory hairy cell leukemia.
    Kreitman RJ; Pastan I
    Hematol Oncol Clin North Am; 2006 Oct; 20(5):1137-51, viii. PubMed ID: 16990113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.
    Müller F; Cunningham T; Stookey S; Tai CH; Burkett S; Jailwala P; Stetler Stevenson M; Cam MC; Wayne AS; Pastan I
    Proc Natl Acad Sci U S A; 2018 Feb; 115(8):E1867-E1875. PubMed ID: 29432154
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.